Press Releases from Apeiron (6 total)
Marketing Approval for Children’s Cancer Immunotherapy in the EU: Outstanding …
May 8, 2017, The European Commission has granted marketing authorization for "Dinutuximab beta Apeiron", an antibody-based immunotherapy of the rare pediatric cancer neuroblastoma. Thanks to…
Neuroblastoma: APEIRON Grants EUSA Pharma Global Rights to Immunotherapy
Vienna, Austria, 04 October 2016 – APEIRON Biologics AG grants EUSA Pharma, UK exclusive global commercialization rights to the oncology product ISQETTE®. ISQETTE® is an…
Apeiron Biologics Establishes Biotech-Spinoff Attoquant Diagnostics
APEIRON Biologics AG (Apeiron) today announced the launch of Attoquant Diagnostics GmbH (Attoquant) as a subsidiary. Attoquant will globally commercialize its already successfully marketed peptide…
Experienced Venture Capitalist/Pharma Manager Joins Apeiron`s Business Developme …
Vienna (Austria), 10 January 2011 - APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a…
Apeiron Acquires Rights To New Clinical Stage Project:
License for therapeutic enzyme for treatment of inflammatory conditions marks first step of project portfolio build-up
APEIRON Biologics AG (Apeiron) today announced that, as part of…
Apeiron Nominated for the Most Important European Biotechnology Award
Vienna-based biotech company Apeiron Biologics AG has been nominated as one of three finalists for the European Biotechnica Award. The Biotechnica Award, which is presented…
Go To Page:
